68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors

Poeppel, Thorsten D; Binse, Ina; Petersenn, Stephan; Lahner, Harald; Schott, Matthias; Antoch, Gerald; Brandau, Wolfgang; Bockisch, Andreas; Boy, Christian (2011). 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. Journal of nuclear medicine, 52(12), pp. 1864-70. New York, N.Y.: Society of Nuclear Medicine 10.2967/jnumed.111.091165

Full text not available from this repository. (Request a copy)

Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of somatostatin receptors (sst). The 2 compounds most often used in functional imaging with PET are (68)Ga-DOTATATE and (68)Ga-DOTATOC. Both ligands share a quite similar sst binding profile. However, the in vitro affinity of (68)Ga-DOTATATE in binding the sst subtype 2 (sst2) is approximately 10-fold higher than that of (68)Ga-DOTATOC. This difference may affect their efficiency in the detection of NET lesions because it is the sst2 that is predominantly overexpressed in NET. We thus compared the diagnostic value of PET/CT with both radiolabeled somatostatin analogs ((68)Ga-DOTATATE and (68)Ga-DOTATOC) in the same NET patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Boy, Christian

ISSN:

0161-5505

Publisher:

Society of Nuclear Medicine

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:19

Last Modified:

06 Dec 2013 13:26

Publisher DOI:

10.2967/jnumed.111.091165

PubMed ID:

22072704

Web of Science ID:

000298162500020

URI:

https://boris.unibe.ch/id/eprint/6162 (FactScience: 211064)

Actions (login required)

Edit item Edit item
Provide Feedback